Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

4.450 -0.110 (-2.41%)

Official Closing Price Updated: 4:15 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

September 13, 2022

Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares!

Via InvestorPlace

Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know ↗

August 26, 2022

Moderna Inc (NASDAQ: MRNA) has

Via Benzinga

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap: Arbutus Biopharma Q2 Earnings ↗

August 04, 2022

Arbutus Biopharma (NASDAQ:ABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Arbutus Biopharma: Q1 Earnings Insights ↗

May 05, 2022

Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners ↗

July 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot ↗

July 06, 2022

The company isn't seeking an injunction, but wants "fair compensation."

Via Investor's Business Daily

Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot ↗

July 05, 2022

The company isn't seeking an injunction, but wants "fair compensation."

Via Investor's Business Daily

This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B ↗

June 28, 2022

Via Benzinga

Morning Brief: Top Financial Stories Dominating on Monday, May 9 ↗

May 09, 2022

CNBC Ford Motor Selling 8M Shares Of Rivian Automotive

Via Benzinga

Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ ↗

May 09, 2022

Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking...

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Arbutus Biopharma Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

April 28, 2022

Arbutus Biopharma (NASDAQ:ABUS) will host a conference call at 08:45 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters ↗

March 18, 2022

Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,

Via Benzinga

Arbutus Biopharma Earnings Perspective: Return On Capital Employed ↗

March 09, 2022

Benzinga Pro data, Arbutus Biopharma (NASDAQ:ABUS) reported Q4 sales of $3.21 million. Earnings fell to a loss of $21.32 million, resulting in a 11.29% decrease from last quarter...

Via Benzinga

Arbutus Biopharma: Q4 Earnings Insights ↗

March 03, 2022

Arbutus Biopharma (NASDAQ:ABUS) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement....

Via Benzinga

Arbutus Hits Moderna With New Suit Claiming COVID-19 Vaccine Patent(s) ↗

February 28, 2022

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Genevant have sued Moderna Inc (NASDAQ: MRNA) for infringing on their patent on a lipid...

Via Benzinga

Futures, Global Markets Soar In Biggest 4-Day Rally Since November 2020 ↗

February 02, 2022

US equity futures and global stocks from Europe to Asia were headed for the biggest four-day rally since November 2020, supercharged by blockbuster earnings AMD and Google, which hit an all time high...

Via Talk Markets

23 Stocks Moving in Wednesday's Pre-Market Session ↗

February 02, 2022

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Also check out: Executives buy more than $600 million of 3...

Via Benzinga

Earnings Scheduled For March 3, 2022 ↗

March 03, 2022

Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022 ↗

February 02, 2022

Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

January 31, 2022

Welcome back, trader! We're ready for another busy week of trading as we start it with the biggest pre-market stock movers for Monday!

Via InvestorPlace

The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective ↗

January 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura...

Via Benzinga

Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street ↗

December 29, 2021

Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current

Via Talk Markets

25 Stocks Moving in Monday's Pre-Market Session ↗

December 20, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) rose 68% to $5.59 in pre-market trading after the company reported addition to the Russell 2000 Index. Verso Corporation (NYSE:...

Via Benzinga

Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board ↗

December 18, 2021

BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai.

Via Talk Markets

How Will Moderna Stock Weather Omicron? — And Other Questions Clouding 2022 ↗

December 16, 2021

Analysts call for a sales and earnings decline in 2022. Can Moderna stave it off?

Via Investor's Business Daily

Why Arbutus Biopharma Shares Are Rising ↗

December 13, 2021

Arbutus Biopharma Corp (NASDAQ: ABUS) shares are trading higher after the company announced it received a $40M upfront payment from Qilu to commercialize AB-729 in Asia...

Via Benzinga

Arbutus Biopharma Shares Jump After Achieving First Milestone Under COVID-19 Pact ↗

December 07, 2021

Arbutus Biopharma Corporation (NASDAQ: ABUS) has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for treating...

Via Benzinga

20 Stocks Moving in Friday's Pre-Market Session ↗

December 03, 2021

Gainers BIOLASE, Inc. (NASDAQ: BIOL) rose 27.2% to $0.52 in pre-market trading. Biolase reporte in Form4 filing that President bought 70,000 shares at an average price of $0.45...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.